hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
In 2004, Gaddafi traveled to the headquarters of the European Union (EU) in Brussels—signifying improved relations between Libya and the EU—and the EU dropped its sanctions on Libya. As a strategic player in Europe's attempts to stem illegal migration from Africa, in October 2010, the EU paid Libya over €50 million to stop African migrants passing into Europe; Gaddafi encouraged the move, saying that it was necessary to prevent the loss of European cultural identity to a new "Black Europe". Gaddafi also completed agreements with the Italian government that they would invest in various infrastructure projects as reparations for past Italian colonial policies in Libya. Italian Prime Minister Silvio Berlusconi gave Libya an official apology in 2006, after which Gaddafi called him the "iron man" for his courage in doing so. In August 2008, Gaddafi and Berlusconi signed a historic cooperation treaty in Benghazi; under its terms, Italy would pay $5 billion to Libya as compensation for its former military occupation. In exchange, Libya would take measures to combat illegal immigration coming from its shores and boost investment in Italian companies. After the US removed Libya from its list of state sponsors of terrorism in 2006, Gaddafi nevertheless continued his anti-Western rhetoric. At the 2008 Arab League summit, held in Syria, he warned fellow Arab leaders that they could be overthrown and executed by the US like Saddam Hussein.
== Awards and recognition == 1997: Newcomb Cleveland Prize 1998: W. Alden Spencer Award 1999: Albert Lasker Basic Medical Research Award 2000: Rosenstiel Award 2001: Gairdner Foundation International Award 2003: Louisa Gross Horwitz Prize 2003: Nobel Prize in Chemistry
=== Detection in body fluids === DMT may be measured in blood, plasma or urine using chromatographic techniques as a diagnostic tool in clinical poisoning situations or to aid in the medicolegal investigation of suspicious deaths. In general, blood or plasma DMT levels in recreational users of the drug are in the 10–30 μg/L range during the first several hours post-ingestion. Less than 0.1% of an oral dose is eliminated unchanged in the 24-hour urine of humans.
21 July The Bodyhunters, about the disappearance of Royal Marine Alan Addis; on 8 August 1980, Royal Marine went missing in North Arm; the Forensic Search Advisory Group, from the Home Office, was founded in 1988 by forensic archaeologist John Hunter of the University of Birmingham, with Sgt Mick Swindells of Lancashire Constabulary, providing the first evidence by an archaeologist in a British court; Swindells had found 5 yr old Rosie McCann, of Moorheys in Oldham, in only a few hours in March 1996, after she had disappeared on 14 January 1996 - the local police had been, conversely, searching for seven weeks and had not found anything in that time, and with the generous assistance of RAF search teams; the FSAG adopted a much different searching approach to typical police methods, with archaeology, more educated guesses, and applied geophysics; the individual was part of Naval Party 8901, to train locals in civil defence in 1980; Islands Radio; the team took ground-penetrating radar and five local policemen; three years previously detectives from Devon and Cornwall Police conducted an investigation and arrested four people - three of those were Titch Jaffray, Burnerd Peck and Tony Blake; the team were conducting a nine-day search in 1997; 80-90% of murders have disposal in known areas to the murderer; Chris Johnson was a former Royal Marine; the team looked in the cemetery first, with ground-penetrating radar, which could detect up to three metres below the surface, for irregularities; Tim Cotter, from the Royal Navy; the team knew that any disused buildings would be a plausible hiding place, as nothing is often suspected; in a search site, the team found mixed, or disturbed, soil. Narrated by Robin Ellis, made with the Discovery Channel 28 July Miracle Police, including the Audrey Santo case; personnel of the Roman Catholic Diocese of Worcester; the investigator Joe Nickell; Peter Gumpel of the Congregation for the Causes of Saints; evolutionary psychologist Robin Dunbar; John Polkinghorne of the University of Cambridge; Karen Armstrong, who wrote A History of God; the Lourdes Medical Bureau; Luigi Bommarito, Archbishop from 1988 to 2002 of the Roman Catholic Archdiocese of Catania. Narrated by Piers Gibbon, directed by Alexander Marengo, made by Ideal World with the Discovery Channel 4 August Dawn of the Death Ray, about the laser and its invention in July 1960; physicist Arthur Schawlow, inventor of the laser; testing of lasers took place at Kirtland Air Force Base, New Mexico, where an aircraft was first brought down with a laser in November 1973; a laser-equipped Boeing KC-135 was operated from 1973, by the 4900th Flight Test Group, led by Col John Otten, taking off in January 1975; fighter aircraft would launch air to air missiles, with insufficient fuel, at the aircraft, and the laser would attempt to shoot the missile down; after three years, on 26 May 1983, the laser shot down its first air to air Sidewinder missile; adverse atmospheric conditions often made an airborne laser ineffective; the White Sands Missile Range in New Mexico, and Leik Myrabo of the USAF Advanced Concepts Division; the 1991 Gulf War allowed much advanced technology to be fully evaluated - and Patriot missiles had mostly missed Iraqi Scud missiles; the Directed Energy Directorate of the Air Force Research Laboratory, and its Starfire Optical Range, and physicist Robert Fugate; John V. Breakwell; the USAF ordered seven airborne attack lasers, for delivery by 2008; Major-General Don Lamberson. Narrated by Michael Bywater, directed by Chris Durlacher, produced by David Dugan, made by Windfall Films 11 August Thin Air, about climbers on Mount Everest; in the 1996, eight participants on an Everest expedition died in one day; above 17,000 ft climbers experience weight loss and sleep loss; Peter Hackett (mountaineer); Ed Viesturs from Seattle; David Breashears, who made the documentary; when he was making a film in May 1996, eight climbers died in the 1996 Mount Everest disaster; climbers fly by helicopter to 9,000 ft, then climb to base camp at 17,600 ft; pulmonologist Brownie Schoene of the University of Washington School of Medicine in Seattle; psychologist Gail Rosenbaum; chronic mountain sickness and the portable hyperbaric bag, which is pumped to 2 PSI; the Khumbu Glacier and Khumbu Icefall; Guy Cotter of Adventure Consultants; the 'death zone' is above 26,000 ft; the Lhotse western face; the team reach the South Col, known as Camp VI; the Hillary Step; pulse oximetry and brain MRI scans are taken in Seattle. Broadcast on PBS as Everest - the death zone, when narrated by Jodie Foster. British edition narrated by Piers Gibbon, directed by David Breashears, made by Nova 18 August The Ten Plagues of Egypt, about the Plagues of Egypt in the Book of Exodus; Avi Weiss, who researched the Book of Exodus; doctor John S. Marr looked at the Ipuwer Papyrus, and worked with Curtis Malloy; marine biologist JoAnn Burkholder of North Carolina State University, and how Pfiesteria piscicida could be the first plague; Richard Wassersug of Dalhousie University in Canada, and a plague of frogs; entomologist Richard Brown of Mississippi State University in Starkville, Mississippi; public health entomologist Andrew Spielman of Harvard T.H. Chan School of Public Health; Roger Breeze of Plum Island Animal Disease Center; the final plague was likely caused by Stachybotrys chartarum, which made mycotoxin. Narrated by Jenni Murray, produced by Peter Spry-Leverton, directed by Bill Eagles, made by UFA GmbH and Café Productions, with The Learning Channel
== Class B peptidomimetics == This class of peptidomimetics encompasses peptides with a large number of non-natural amino acids, major backbone modifications or larger non-natural building fragments that resemble the conformation of a particular peptide binding motif. Examples involve D-peptide and peptidic foldamers such as beta-peptides.
Sources: en.wikipedia.org
=== Gut === Eluxadoline is a peripherally restricted KOR agonist as well as MOR agonist and DOR antagonist that has been approved for the treatment of diarrhea-predominant irritable bowel syndrome. Asimadoline and fedotozine are selective and similarly peripherally restricted KOR agonists that were also investigated for the treatment of irritable bowel syndrome and reportedly demonstrated at least some efficacy for this indication but were ultimately never marketed.
=== Antibacterial use === Tigecycline is used to treat different kinds of bacterial infections, including complicated skin and structure infections, complicated intra-abdominal infections and community-acquired bacterial pneumonia. Tigecycline is a glycylcycline antibiotic that covers MRSA and Gram-negative organisms:
Hydrogen peroxide is used as a potent antimicrobial agent when cells are infected with a pathogen. Catalase-positive pathogens, such as Mycobacterium tuberculosis, Legionella pneumophila, and Campylobacter jejuni, make catalase to deactivate the peroxide radicals, thus allowing them to survive unharmed within the host. Like alcohol dehydrogenase, catalase converts ethanol to acetaldehyde, and drop-out studies in rodents suggest that it may be responsible for the majority of this reaction in the brain.
While the Rockefeller doctors working in tropical locales such as Mexico emphasized scientific neutrality, they had political and economic aims to promote the value of public health to improve American relations with the host country. Although they claimed the banner of public health and humanitarian medicine, they often engaged with politics and business interests. Rhoads was involved in a racism whitewashing scandal in the 1930s during which he joked about injecting cancer cells into Puerto Rican patients, inspiring Puerto Rican nationalist and anti-colonialist leader Pedro Albizu Campos. Noguchi was also involved in an unethical human experimentation scandal. Susan Lederer, Elizabeth Fee, and Jay Katz are among the modern scholars who have researched this period. Researchers with the foundation including Noguchi developed the vaccine to prevent yellow fever. Rhoads later became a significant cancer researcher and director of Memorial Sloan-Kettering, though his eponymous award for oncological excellence was renamed after the scandal reemerged.
== Function == The primary function of DPEP1 is to hydrolyze various dipeptides in renal metabolism. Specifically, it has been found to hydrolyze glutathione and its conjugates such as leukotriene D (Kozak and Tate, 1982). Several pieces of evidence suggest that DPEP1 is also responsible for the hydrolysis of the beta-lactam ring of various THM-class antibiotics, such as penem and carbapenem (Campbell et al., 1984). First, the metabolism of these THM-class antibiotics is known to be localized in the kidney, specifically by a membrane-bound protein. Second, the metabolism of these antibiotics is significantly hindered when the zinc concentration is altered, suggesting the enzyme responsible for the drugs’ metabolism is a zinc-metalloenzyme. Finally, when DPEP1 was experimentally added to penem and carbapenem antibiotics in vitro, the resulting products were structurally identical to their respective metabolites found in an organism's urine (8). The hydrolysis of these antibiotics hinders their antibacterial capabilities, so information on the specific structure of DPEPI is highly sought after in order to find viable inhibitors that could be taken along with these antibiotics to make them more effective. Earlier, beta-lactamase enzymes were thought to occur only in bacteria, where their probable function was in protecting the organisms against the action of beta-lactam antibiotics. These antibiotics exhibit selective toxicity against bacteria but virtual inertness against many eukaryotic cells (Adachi et al., 1990).[supplied by OMIM]
Sources: en.wikipedia.org
Another use for nuclear magnetic resonance is data acquisition in the petroleum industry for petroleum and natural gas exploration and recovery. Initial research in this domain began in the 1950s, however, the first commercial instruments were not released until the early 1990s. A borehole is drilled into rock and sedimentary strata into which nuclear magnetic resonance logging equipment is lowered. Nuclear magnetic resonance analysis of these boreholes is used to measure rock porosity, estimate permeability from pore size distribution and identify pore fluids (water, oil and gas). These instruments are typically low field NMR spectrometers. NMR logging, a subcategory of electromagnetic logging, measures the induced magnet moment of hydrogen nuclei (protons) contained within the fluid-filled pore space of porous media (reservoir rocks). Unlike conventional logging measurements (e.g., acoustic, density, neutron, and resistivity), which respond to both the rock matrix and fluid properties and are strongly dependent on mineralogy, NMR-logging measurements respond to the presence of hydrogen. Because hydrogen atoms primarily occur in pore fluids, NMR effectively responds to the volume, composition, viscosity, and distribution of these fluids, for example oil, gas or water. NMR logs provide information about the quantities of fluids present, the properties of these fluids, and the sizes of the pores containing these fluids. From this information, it is possible to infer or estimate:
The first effect—the loss of AMP—is mostly significant because AMP contains ribose, a sugar molecule that is also used to make DNA, RNA, and some enzymes. Though the body can manufacture some ribose and obtain more from RNA-rich sources such as beans and red meat, this loss of ribose due to MADD is sometimes sufficient to create a shortage in the body, resulting in symptoms of severe fatigue and muscle pain. This outcome is especially likely if the individual regularly exercises vigorously or works physically over a period of weeks or months. The second effect, the absence of ammonia, is not well understood. It may result in a reduction of the amount of fumarate available to the citric acid cycle, and it may result in lower levels of nitric oxide (a vasodilator) in the body, reducing blood flow and oxygen intake during vigorous exercise, though this may be offset by increased levels of adenosine, another vasodilator. The third effect, the reduction in IMP, is also not well understood. It may somehow result in a reduction in the amount of lactic acid produced by the muscles, though serum lactate is typically slightly elevated with MADD. The following is a very simplified model of what may be going on inside a muscle cell with AMPD deficiency. There are two major semi-stable states: one with intra-cellular glycogen available, and one with glycogen exhausted. Both states are modified by how much the citric acid cycle is down-regulated by default. Start from the state where glycogen is available and the citric acid cycle is severely down-regulated.
=== Birth rate === According to one report, in 1924, shortly after the Free State's establishment, the new dominion had the "lowest birth-rate in the world". The report noted that amongst countries for which statistics were available (Ceylon, Chile, Japan, Spain, South Africa, the Netherlands, Canada, Germany, Australia, the United States, Britain, New Zealand, Finland, and the Irish Free State), Ceylon had the highest birth rate at 40.8 per 1,000 while the Irish Free State had a birth rate of just 18.6 per 1,000.
== Biology and biochemistry == S. haemolyticus is nonmotile, nonsporulating, facultatively anaerobic, and Gram-positive. Cells are typically coccus-shaped and range from 0.8 to 1.3 μm in diameter. It lives on a wide variety of substrates, including glucose, glycerol, maltose, sucrose, and trehalose. It also tests positive for acetoin production, arginine, dihydrolase, benzidine, catalase, hemolysis, and lipase; it tests negative for coagulase, DNase, ornithine decarboxylase and phosphatase
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.